People: Sangamo BioSciences Inc (SGMO.O)

Summary

Name	Age	Since	Current Position
William Ringo	67	2010	Independent Chairman of the Board
Edward Lanphier	55	1995	President, Chief Executive Officer, Director
H. Ward Wolff	63	2007	Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President
Geoffrey Nichol	57	2011	Executive Vice President - Research and Development
Philip Gregory	41	2009	Vice President - Research, Chief Scientific Officer
Dale Ando	58	2004	Vice President - Therapeutic Development, Chief Medical Officer
Paul Cleveland	55	2008	Independent Director
Stephen Dilly	52	2010	Independent Director
John Larson	77	1996	Independent Director
Steven Mento	60	2005	Independent Director
Thomas Wiggans	61	2008	Independent Director
Elizabeth Wolffe			IR Contact Officer, Corporate Communications

» Insider Trading

Biographies

Name	Description
William Ringo	Mr. William R. Ringo, Jr., is Independent Chairman of the Board of Sangamo BioSciences Inc., since April 16, 2010. From April 2008 until his retirement in April 2010, Mr. Ringo was the Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc. and was responsible for guiding Pfizer’s overall strategic planning and business development activities. Prior to joining Pfizer, he served as an executive in residence at Warburg Pincus and Sofinnova Ventures. From August 2004 to April 2006, Mr. Ringo was President and Chief Executive Officer of Abgenix, Inc., a biotechnology firm focused on developing human antibodies as agents to treat cancer and other serious diseases. At Abgenix, he led efforts to transform the organization into a more focused product company by strengthening the senior management team and enhancing an existing partnership with Amgen, which acquired Abgenix in 2006. Mr. Ringo began his career at Eli Lilly & Company in 1973 and during his 28-year tenure he held a number of senior positions, including Product Group President for Oncology and Critical Care, President of Internal Medicine Products, President of the Infectious Diseases Business Unit and Vice President of Sales and Marketing for U.S. Pharmaceuticals. He retired from Lilly in 2001. From 2001 to 2007, he served on various boards of directors, including Encysive Pharmaceuticals, Inc., Inspire Pharmaceuticals, Inc. and InterMune, Inc. where he was the non-executive chairman of the Board of Directors after serving as interim Chief Executive Officer from June to September 2003. Mr. Ringo serves on the Board of Directors of BioCrossroads, a public-private collaboration of corporate, university, government and entrepreneurial leaders that supports Indiana’s life sciences research and corporate strengths in life sciences while encouraging business development in the region. He received a B.S. in Business Administration and an M.B.A. from the University of Dayton.
Edward Lanphier	Mr. Edward O. Lanphier II, is President, Chief Executive Officer, Director of Sangamo BioSciences, Inc., since its inception in 1995. He is the founder of the Company. Mr. Lanphier has over thirty years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporation, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, Mr. Lanphier was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, Mr. Lanphier served as Vice President of Corporate Development at Biotherapeutics, Inc. From 1984 to 1986 he served as Vice President of Corporate Development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute and the Dean’s Advisory Board of the University of Michigan School of Public Health. Mr. Lanphier received a B.A. in biochemistry from Knox College.
H. Ward Wolff	Mr. H. Ward Wolff is Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President of Sangamo BioSciences, Inc., since December 2007. Mr. Wolff served as a member of the Company’s Board of Directors and the Audit Committee from June 2006 through December 2007. Prior to joining the Company, Mr. Wolff served as Senior Vice President, Finance and Chief Financial Officer of Nuvelo, Inc. (now ARCA biopharma, Inc.) from July 2006 to August 2007 and Chief Financial Officer and Senior Vice President, Finance, of Abgenix, Inc. from September 2004 to April 2006. From July 2002 to December 2003, Mr. Wolff served as Chief Financial Officer of QuantumShift. From 1998 to January 2002, he was Senior Vice President and Chief Financial Officer of DoubleTwist, Inc. From 1992 to 1998, he was Senior Vice President of Finance and Administration and Chief Financial Officer of Premenos Technology Corporation. From 1985 to 1992, Mr. Wolff was an Executive Director of Russell Reynolds Associates, Inc. From 1974 to 1985, Mr. Wolff held numerous positions with Price Waterhouse & Co., as a certified public accountant, including Senior Audit Manager. Mr. Wolff currently serves on the boards of directors of Portola Pharmaceuticals, Inc. and MAP Pharmaceuticals, Inc. Mr. Wolff received a B.A. in Economics from the University of California at Berkeley and an M.B.A. from Harvard Business School.
Geoffrey Nichol	Dr. Geoffrey M. Nichol, B.Med.Sc., M.B., Ch.B., M.B.A., has been appointed as Executive Vice President - Research and Development of Sangamo BioSciences, Inc., effective July 11, 2011. Dr. Nichol has over twenty years of experience in the pharmaceutical and biotechnology industries and has made contributions in all stages of the drug development process from program initiation, through all phases of clinical evaluation to product approval. He has been closely associated with the development of over 15 new drug candidates and the approval and/or launch of several marketed drugs, including Augmentin BID, Foradil® and Yervoy™. Dr. Nichol has particular in development of platform technologies. From 2002 to 2010 he served as Senior Vice President of Product Development at Medarex, Inc. where he was responsible for all aspects of the clinical development of therapeutic products based on a fully-human monoclonal antibody platform. From 1996 to 2002, he held various senior management positions at Novartis Pharmaceuticals, including Vice President, US Medical Affairs and Vice President and Global Head, Project Management, and in the seven years prior held management positions in drug development with SmithKline Beecham Pharmaceuticals. Most recently, Dr. Nichol has been Chief Medical Officer of Ikaria Inc., a biotherapeutics company. Dr. Nichol earned his B.Med.Sc., M.B., Ch.B., or the equivalent of an M.D. in the U.S., from Otago University Medical School in New Zealand and received an M.B.A. from Warwick University in the United Kingdom
Philip Gregory	Dr. Philip D. Gregory, Ph.D. is Vice President - Research, Chief Scientific Officer of Sangamo BioSciences, Inc. He has served as Chief Scientific Officer since July 2009 and Vice President, Research since October 2005. He joined Sangamo in December 2000 as a Scientist, became a Team Leader in October 2001 and Senior Director, Research in July 2003. Prior to joining the company, Dr. Gregory was at the University of Munich, Germany. He has served as a member of the Scientific Advisory Board of the Keystone Symposia since December 2009. Dr. Gregory received a D. Phil. in biochemistry from the University of Oxford and a B.Sc. in microbiology from the University of Sheffield.
Dale Ando	Dr. Dale G. Ando, M.D. is Vice President - Therapeutic Development, Chief Medical Officer of Sangamo BioSciences, Inc., since August 2004. Dr. Ando has held senior positions in therapeutic product development in several biotechnology companies. From 1997 until he joined Sangamo in 2004, he was Vice President, Clinical Research at Cell Genesys, Inc. While at Cell Genesys, Dr. Ando directed the development of Phase I-III GVAX programs, oncolytic virus programs and Phase I/ II trials of chimaeric T-cell receptor products in HIV and cancer. From 1992 to 1997, Dr. Ando served as director of clinical gene therapy at Chiron Corporation. From 1997 to 2001 Dr. Ando served as a member of the Recombinant DNA Advisory Committee (RAC) and the Adenoviral Safety Committee for the National Institutes of Health (NIH). Dr. Ando began his career as a faculty member at UCLA Medical School in the Division of Rheumatology. He received his M.D. and Internal Medicine training at the University of Michigan and a B.S. in Chemistry from Stanford University. Dr. Ando is board certified in internal medicine and is a subspecialist in Rheumatology.
Paul Cleveland	Mr. Paul B. Cleveland is Independent Director of Sangamo Biosciences, Inc., since November 2008. Mr. Cleveland is Chairman of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Mr. Cleveland is currently General Partner and Chief Operating Officer of Mohr Davidow Ventures. From January 2006 through February 2011, Mr. Cleveland served as Executive Vice President, Corporate Development and Chief Financial Officer of Affymax, Inc., a biopharmaceutical company focusing on the treatment of serious and life-threatening conditions. From April 2004 to December 2005, he served as a managing director at Integrated Finance, Ltd., an investment bank. From September 1996 to April 2003, he served as a managing director at J.P. Morgan Chase and Co. (and a predecessor firm, Hambrecht & Quist), an investment bank. From January 1993 to September 1996, he was a partner at Cooley Godward LLP, a law firm. From December 1988 to December 1992, he was a corporate attorney at Sidley Austin LLP, a law firm, and from September 1981 to November 1988, he was a corporate attorney at Davis Polk & Wardwell, a law firm. Mr. Cleveland received a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.
Stephen Dilly	Dr. Stephen G. Dilly, M.B.B.S., Ph.D. is Independent Director of Sangamo BioSciences, Inc. He is a member of the Audit Committee and is the Chairman of the Clinical Review Committee. Dr. Dilly is currently Chief Executive Officer of PhotoThera. Inc., a medical device company with a product in Phase III clinical trials for treatment of ischemic stroke. From 2006 to December 2011, Dr. Dilly served as President and Chief Executive Officer and a member of the Board of Directors of APT Pharmaceuticals, Inc.. From 2007 to 2009, he served as a member of the board of directors of Avigen, Inc., a biopharmaceutical company which merged with MediciNova, Inc. in December 2009. From 2003 to 2006, he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003, he held various management positions at Genentech Inc., including Vice President of Development Sciences from 2002 to 2003. From 1988 to 1998, Dr. Dilly held various management positions in drug development with SmithKline Beecham in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly currently serves as a member of the Advisory Board of Physic Ventures and the National Board of Advisors of the UC Davis Health System. In 1982, Dr. Dilly received an M.B.B.S., the equivalent of an M.D. in the U.S., from the University of London in the U.K. and a Ph.D. in Cardiac Physiology from University of London in 1988.
John Larson	Mr. John W. Larson is Independent Director of Sangamo BioSciences, Inc., since January 1996. Mr. Larson is Chairman of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. From February 2003 to December 2009, Mr. Larson served as a partner at the law firm of Morgan, Lewis & Bockius LLP. From 1969 to January 2003, Mr. Larson served as partner at the law firm of Brobeck, Phleger & Harrison LLP (Brobeck), except for the period from July 1971 to September 1973 when he was in government service as Assistant Secretary of the United States Department of the Interior and Counselor to George P. Shultz, Chairman of the Cost of Living Council. From 1988 until March 1996, Mr. Larson was Chief Executive Officer of Brobeck. Mr. Larson serves on the boards of directors of Needham Funds, WageWorks, Inc. and MBA Polymers, Inc. Mr. Larson received a L.L.B. and a B.A., with distinction, in economics, from Stanford University.
Steven Mento	Dr. Steven J. Mento, Ph.D., is Independent Director of Sangamo BioSciences, Inc., since May 2005. He is a member of the Audit Committee and the Nominating and Corporate Governance Committee. He is President and Chief Executive Officer of Conatus Pharmaceuticals Inc. From 1997 to 2005 he was President and Chief Executive Officer of Idun Pharmaceuticals and prior to that, from 1982 to 1992, Dr. Mento held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January of 1992, he joined Viagene, Inc. as Vice President of Research and Development. Dr. Mento was responsible for directing the company’s transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. In October of 1995, Chiron Corporation acquired Viagene, Inc., and renamed the company Chiron Viagene, Inc. Dr. Mento served as President of Chiron Viagene, Inc. and Vice President of Chiron Corporation until August of 1997. Dr. Mento currently serves on the boards of BIOCOM, the Biotechnology Industry Organization (BIO), the BIO ECS Governing Body, the BIO Health Section Governing Body, the Donald P. Shiley BioScience Center at SDSU Scientific Advisory Board and Cal State San Marcos Advisory Council. Dr. Mento received a Bachelor of Arts, Master of Science, and a Ph.D. in microbiology from Rutgers University. He completed his post-doctoral fellowship in somatic cell genetics at the University of Toronto.
Thomas Wiggans	Mr. Thomas G. Wiggans is Independent Director of Sangamo BioSciences, Inc., since June 2008. Mr. Wiggans is a member of the Compensation Committee. In September 2010, Mr Wiggans founded and became Chief Executive Officer of Dermira, a private biotechnology company focused on developing and commercializing innovative new therapies in dermatology. He formerly served as Chairman and Chief Executive Officer of Peplin, Inc., which was acquired by LEO Pharma of Copenhagen, Denmark in November 2009. Prior to joining Peplin he served as Chief Executive Officer of Connetics Corporation, a biotechnology company, from 1994, and as Chairman of the Board from January 2006, until December 2006 when Connetics Corporation was acquired by Stiefel Laboratories. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics, a biotechnology company. From 1980 to 1992, Mr. Wiggans served in various positions at Ares-Serono Group, a pharmaceutical company, including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans currently serves as a member of the boards of directors of Onyx Pharmaceuticals Inc., Somaxon Pharmaceuticals and Lithera, Inc., and the Board of Trustees of the University of Kansas Endowment Association. In addition, he is Chairman of the Biotechnology Institute, a non-profit educational organization. Mr. Wiggans received a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.
Elizabeth Wolffe

Basic Compensation

Name	Fiscal Year Total
William Ringo	--
Edward Lanphier	1,150,000
H. Ward Wolff	678,750
Geoffrey Nichol	1,836,900
Philip Gregory	513,375
Dale Ando	635,875
Paul Cleveland	--
Stephen Dilly	--
John Larson	--
Steven Mento	--
Thomas Wiggans	--
Elizabeth Wolffe	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
William Ringo	0	0
Edward Lanphier	1,150,000	6,476,000
H. Ward Wolff	0	0
Geoffrey Nichol	0	0
Philip Gregory	248,500	247,352
Dale Ando	275,000	84,000
Paul Cleveland	0	0
Stephen Dilly	0	0
John Larson	0	0
Steven Mento	0	0
Thomas Wiggans	0	0
Elizabeth Wolffe	0	0

Insider Trading

Name	Shares Traded	Price
LARSON JOHN WILLIAM	10,000	$2.45
GREGORY PHILIP D	6,000	$3.45
GREGORY PHILIP D	6,000	$10.09
ANDO DALE GENJI	15,000	$3.61
ANDO DALE GENJI	15,000	$10.72
LANPHIER EDWARD O II	190	$10.00
LANPHIER EDWARD O II	5,000	$10.00
WOLFF HENRY WARD	10,000	$3.45
WOLFF HENRY WARD	10,000	$10.00
GREGORY PHILIP D	6,000	$9.54
GREGORY PHILIP D	6,000	$3.45
LANPHIER EDWARD O II	12,000	$0.00
ANDO DALE GENJI	5,800	$3.61
ANDO DALE GENJI	15,000	$9.18
ANDO DALE GENJI	9,200	$3.61
GREGORY PHILIP D	6,000	$10.00
GREGORY PHILIP D	6,000	$4.92
WOLFF HENRY WARD	10,000	$3.45
LANPHIER EDWARD O II	25,000	$10.00
WOLFF HENRY WARD	10,000	$10.00
ANDO DALE GENJI	15,000	$3.61
ANDO DALE GENJI	15,000	$8.64
GREGORY PHILIP D	6,000	$9.53
GREGORY PHILIP D	6,000	$4.92
ANDO DALE GENJI	15,000	$3.61

» Full list on Insider Trading

People: Sangamo BioSciences Inc (SGMO.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: